Breast Cancer Therapy

Shares of Merrimack Pharmaceuticals Inc (NASDAQ: MACK) fell more than 20 percent early Wednesday morning after the company announced that it will stop a Phase 2 study of its treatment to fight breast cancer. The Phase 2 study was called HERMIONE and evaluated its only drug MM-302, an antibody-...